Immuneering Corporation
IMRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $189.1M
$5.21
▲ +1.17%
P/E
-5.01
Mkt Cap
$189.1M
52-Wk Range
$3.86–$10.08
52-Week Range
$3.86 - $10.08
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 0.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary dual-MEK inhibitor technology for RAS/RAF-mutated cancers
- Focused pipeline targeting validated MAPK and mTOR pathways
- Pharmaceutical expertise inherited from Teva Pharmaceutical Industries parent
- Clinical-stage assets with potential for significant market expansion in oncology
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
IMM-1-104 clinical trial progression and regulatory milestones
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-2.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IMRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 5, 2026
Reported EPS of -$0.27 vs -$0.26 consensus (-2.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$361.0K
Margins · last 8Q
Gross
50.0%
Profit
-4784.6%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 27, 2026
vs Industry
How IMRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related